MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028

Lifesciences | Healthcare & Wellness

MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028

Market By Type, Industry Verticals, And Country | Forecast 2021-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

As denoted in Triton Market Research’s report, the non-alcoholic steatohepatitis (NASH) biomarker market in the Middle East and Africa is foreseen to register growth based on value at a CAGR of 21.48% during the anticipated period 2021-2028.


Report scope can be customized per your requirements. Request For Customization

The countries evaluated in this market are:

        The United Arab Emirates

        Turkey

        South Africa

        Saudi Arabia

        Rest of Middle East & Africa

In Middle East and Africa, the studied market is expected to witness substantial growth, owing to the rise in the prevalence of NASH, enhancements in the healthcare sector, and an increase in awareness towards non-alcoholic steatohepatitis therapeutics. For instance, in Saudi Arabia, there is a tremendous surge in the number of NASH cases than non-alcoholic fatty liver diseases. Besides, the rise in obesity levels is adding to the occurrence of NASH cases across the country.

Further, obesity can directly lead to cardiovascular diseases, metabolic disorders, and even cancer. Here, as per statistics, a majority of the population is obese, resulting in higher deaths caused by obesity across Saudi Arabia. Thus, the growing number of obese and diabetic patients increases the emergence of NASH, which is estimated to contribute to developing the non-alcoholic steatohepatitis biomarker market in the upcoming years.

Furthermore, the reviewed market is estimated to gain traction in the UAE, owing to the rise in obesity, as well as type 2 diabetes mellitus. According to the National Institute of Health, the occurrence rate of non-alcoholic fatty liver disease is rising and is likely to surge rapidly until 2030. Along with this, the rise in the obesity rate has increased demand for various surgeries, such as bariatric surgery. Hence, the prevalence of such conditions holds the potential to drive the NASH biomarker market’s growth over the estimated period.

Pfizer Inc is a biopharmaceutical company involved in manufacturing and marketing products, such as vaccines, drugs, and consumer healthcare products. It provides its products for the treatment of respiratory, cardiovascular, and gastrointestinal diseases, among others. Pfizer has operations across various regions, including Middle East and Africa.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. KEY INSIGHTS

2.1.1. DEMAND FOR NASH BIOMARKERS

2.1.2. UNMET MEDICAL NEEDS

2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTE PRODUCTS

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR LANDSCAPE

2.6. KEY MARKET STRATEGIES

2.6.1.   CONTRACTS & PARTNERSHIPS

2.6.2.   BUSINESS EXPANSIONS & DIVESTITURES

2.6.3.   ACQUISITIONS & MERGERS

2.6.4.   NEW PRODUCT LAUNCHES

2.7. MARKET DRIVERS

2.7.1. RISING PREVALENCE OF NASH

2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES

2.8. MARKET RESTRAINTS

2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS

2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

2.9. MARKET OPPORTUNITIES

2.9.1. GROWTH OPPORTUNITIES IN DEVELOPING REGIONS

2.9.2. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE

3. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE

3.1. SERUM BIOMARKER

3.2. HEPATIC FIBROSIS BIOMARKER

3.3. APOPTOSIS BIOMARKER

3.4. OXIDATIVE STRESS BIOMARKER

3.5. OTHER TYPES

4. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS

4.1. PHARMA & CRO INDUSTRY

4.2. DIAGNOSTIC LAB

4.3. ACADEMIC RESEARCH KEY

4.4. HOSPITAL

5. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - COUNTRY OUTLOOK

5.1. SAUDI ARABIA

5.2. UNITED ARAB EMIRATES

5.3. TURKEY

5.4. SOUTH AFRICA

5.5. REST OF MIDDLE EAST & AFRICA

6. COMPETITIVE LANDSCAPE

6.1. ALLERGAN

6.2. ASTRAZENECA

6.3. BRISTOL MYERS SQUIBB COMPANY

6.4. GENFIT SA

6.5. GILEAD SCIENCES INC

6.6. MADRIGAL PHARMACEUTICALS

6.7. MERCK & CO

6.8. NOVARTIS AG

6.9. NOVO NORDISK

6.10. PFIZER INC

6.11. SIEMENS HEALTHINEERS

6.12. VIKING THERAPEUTICS

6.13. ZYDUS CADILA

7. RESEARCH METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE & DELIVERABLES

7.1.1. OBJECTIVES OF STUDY

7.1.2. SCOPE OF STUDY

7.2. SOURCES OF DATA

7.2.1. PRIMARY DATA SOURCES

7.2.2. SECONDARY DATA SOURCES

7.3. RESEARCH METHODOLOGY

7.3.1. EVALUATION OF PROPOSED MARKET

7.3.2. IDENTIFICATION OF DATA SOURCES

7.3.3. ASSESSMENT OF MARKET DETERMINANTS

7.3.4. DATA COLLECTION

7.3.5. DATA VALIDATION & ANALYSIS

List of table

TABLE 1:       MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 2:       VENDOR LANDSCAPE

TABLE 3:       LIST OF CONTRACTS & PARTNERSHIPS

TABLE 4:       LIST OF BUSINESS EXPANSIONS & DIVESTITURES

TABLE 5:       LIST OF ACQUISITIONS & MERGERS

TABLE 6:       LIST OF NEW PRODUCT LAUNCHES

TABLE 7:       MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 8:       MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)

TABLE 9:       MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

List of Figures

FIGURE 1:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 2:     PORTER’S FIVE FORCES ANALYSIS

FIGURE 3:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)

FIGURE 4:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 5:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 6:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 7:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 8:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)

FIGURE 9:     MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)

FIGURE 10:  MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)

FIGURE 11:  MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)

FIGURE 12:  MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)

FIGURE 13:  MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)

FIGURE 14:  SAUDI ARABIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 15:  UNITED ARAB EMIRATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 16:  TURKEY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 17:  SOUTH AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 18:  REST OF MIDDLE EAST & AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;